Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olivero

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Neuropharmacology|February 7, 2018
Environmental training is beneficial to clinical symptoms and cortical presynaptic defects in mice suffering from experimental autoimmune encephalomyelitisT Bonfiglio, G Olivero, M Vergassola, et al.
Pharmaceutical Research|May 1, 1998
Stability of alkoxycarbonylamidine prodrugsZ Shahrokh, E Lee, A G Olivero, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 16, 2011
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
Bioorganic & Medicinal Chemistry|January 30, 1999
Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonistsK D Robarge, M S Dina, T C Somers, et al.
Neuropharmacology|March 27, 2018
The reduction in glutamate release is predictive of cognitive and emotional alterations that are corrected by the positive modulator of AMPA receptors S 47445 in perinatal stressed ratsS Morley-Fletcher, A R Zuena, J Mairesse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
The Journal of Biological Chemistry|January 6, 2005
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivoAlan G Olivero, Charles Eigenbrot, Richard Goldsmith, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Nicole Blaquiere, Vickie Tsui, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTORTimothy P Heffron, Chudi O Ndubaku, Laurent Salphati, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Neuropharmacology|February 7, 2018
Environmental training is beneficial to clinical symptoms and cortical presynaptic defects in mice suffering from experimental autoimmune encephalomyelitisT Bonfiglio, G Olivero, M Vergassola, et al.
Pharmaceutical Research|May 1, 1998
Stability of alkoxycarbonylamidine prodrugsZ Shahrokh, E Lee, A G Olivero, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 16, 2011
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
Bioorganic & Medicinal Chemistry|January 30, 1999
Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonistsK D Robarge, M S Dina, T C Somers, et al.
Neuropharmacology|March 27, 2018
The reduction in glutamate release is predictive of cognitive and emotional alterations that are corrected by the positive modulator of AMPA receptors S 47445 in perinatal stressed ratsS Morley-Fletcher, A R Zuena, J Mairesse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
The Journal of Biological Chemistry|January 6, 2005
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivoAlan G Olivero, Charles Eigenbrot, Richard Goldsmith, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Nicole Blaquiere, Vickie Tsui, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTORTimothy P Heffron, Chudi O Ndubaku, Laurent Salphati, et al.
Pageof 9